Background: In most studies comparing 5-fluorouracil (5-FU) monotherapy versus the combination of folinic acid and 5-FU in the treatment of advanced colorectal cancer, a low dose of 5-FU was given in monotherapy, possibly leading to impaired results in these groups. In a further study we therefore compared the combination treatment with an intensive 5-FU monotherapy regimen with a loading course followed by weekly injections. Patients and Methods: Patients were randomized to receive either 5-FU 370 mg/m2 i.v. days 1-5, followed by weekly administrations of 5-FU 600 mg/m2 or the same doses of 5-FU preceded by folinic acid 200 mg/m2. Because of toxicity, the weekly 5-FU dose in the combination treatment group was reduced to 500 mg/m2 in the second part of the study. Results: Overall, 144 patients were treated. 42 patients received combination therapy and 41 monotherapy before treatment dose modification (part 1). After dose reduction, 31 patients had combination therapy and 30 monotherapy (part 2). Treatment resulted in a complete or partial remission in 11 patients (26%) on combination therapy with the higher and 14 (45%) with the lower weekly dose of 5-FU as compared to 24 and 27%, respectively, treated with monotherapy. In the first part, neither time to progression nor overall survival was statistically different between the treatment groups. After treatment modification, time to progression was significantly longer with combination therapy compared to monotherapy. In both parts, there was no significant difference in survival time between the groups as a whole. However, patients with extensive metastatic disease had a survival benefit when treated with the modified combination therapy as compared to monotherapy. The main toxicity was diarrhea during weekly therapy. This was especially true for patients receiving combination treatment before the reduction of the 5-FU dosage. By reducing 5-FU dosage during weekly therapy, severe diarrhea could be clearly reduced. Conclusions: In patients with advanced colorectal cancer, combination treatment with folinic acid and the reduced form of 5-FU 500 mg/m2 weekly is well tolerated and significantly prolongs relapse-free and, in subgroups, even overall survival as compared to an intensive 5-FU monotherapy regimen.

Keywords:
Colorectal carcinoma, Chemotherapy, 5-Fluorouracil, Folinic acid
This content is only available via PDF.
© 1993 S. Karger AG, Basel
1993
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.